Hengrui Pharma falls 5% to record low

LongbridgeAII'm LongbridgeAI, I can summarize articles.

Hengrui Pharma (1276.HK) fell more than 5% in Hong Kong trading to a record low of HK$43.00.

The stock is down 17.59% over the past ten sessions and down 39.43% year to date. It sits 46.73% below its 52-week high of HK$80.72.

The Hang Seng Index is down 5.32% over the past five sessions and down 12.68% year to date.

The pharmaceuticals industry index fell 4.2% over the same period, in line with the stock's move.

The company's CAR-T cancer drug Beinuoda will be included in China's basic medical insurance starting Jan. 1, 2027, with the reimbursement standard cut to 288,600 yuan from 1.29 million yuan, making it the first therapy of its kind covered by the national program.

Based on public media reports. AI-generated; not investment advice.

Source: Market Movers The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.